3 Small-Cap Biotech Stocks That Could be Poised to Explode

Aerie Pharmaceuticals Inc (NASDAQ:AERI)

Who Bought Shares: Director Gerald Cagle

How Many Shares Were Bought: 1,000 @ $50.25 per share

Date of the Transaction(s): May 21

Director Gerald Cagle was the first Aerie Pharmaceuticals Inc (NASDAQ:AERI) insider to purchase shares of the company in a year when he snatched up 1,000 shares on Monday to raise his ownership in the company to 15,050 shares. Aerie shares sank below $50 earlier this month for the first time since last September, but have rallied by nearly 10% since May 10.

Aerie Pharmaceuticals Inc (NASDAQ:AERI) launched its first FDA-approved drug, the glaucoma treatment Rhopressa, earlier this month. Sales of that drug are expected to be between $20 and $30 million this year, rising to as much as $100 million in 2019. Last week, it submitted another glaucoma treatment, Roclatan, for FDA approval, which is expected to take ten months. That treatment, which is a fixed-dose combination of Rhopressa and latanaprost, has delivered exceptional results in several trials and could have even greater commercial potential than Rhopressa.

In addition to the insider purchase, we recently identified Aerie Pharmaceuticals Inc (NASDAQ:AERI) as one of Five Stocks To Buy According To Top Biotech-Focused Funds. As of March 31, Aerie was owned by several prominent biotech-focused hedge funds, including OrbiMed Advisors, Julian Baker and Felix Baker’s Baker Bros Advisors, Christopher Medlock James’ Partner Fund Management, and James E. Flynn‘s Deerfield Management.

Editas Medicine Inc (NASDAQ:EDIT)

Who Bought Shares: Directors Jessica Hopfield and James Mullen

How Many Shares Were Bought: 6,700 @ $37.28 per share and 10,000 @ $38.03 per share respectively

Date of the Transaction(s): May 17 – 18

Two different directors on Editas Medicine Inc (NASDAQ:EDIT)’s board purchased shares last week, and like at Aerie, they were the first insider purchases by a company insider in nearly a year. The purchases came on the heels of the genome editing company’s shares sliding by over 10% on May 18, the same day it released data from a pre-clinical study of EDIT101.

That data showed that EDIT101, an experimental treatment for Leber Congenital Amaurosis, which can lead to blindness in children, was well tolerated by the non-human primates tested in the study. Additionally, it was observed that an immunity to either AAV5 or Staph. aureus Cas9 did not negatively impact the treatment’s efficacy. EDIT101 uses Cas9 to edit the CEP290 gene, mutations in which are a leading cause of Leber Congenital Amaurosis.

Disclosure: None